Cargando…
Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxyandrostenedione.
Plasma and urinary oestrogens were measured in nine breast cancer patients (eight postmenopausal women and one man) before and during treatment with the aromatase inhibitor 4-hydroxyandrostenedione. Urinary oestrogens were measured by using a highly specific GC-MS method. Plasma levels of oestrone,...
Autores principales: | Johannessen, D. C., Adlercreutz, H., Fotsis, T., Lønning, P. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968556/ https://www.ncbi.nlm.nih.gov/pubmed/8135918 |
Ejemplares similares
-
Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
por: MacNeill, F. A., et al.
Publicado: (1994) -
4-hydroxyandrostenedione--further clinical and extended endocrine observations.
por: Pickles, T., et al.
Publicado: (1990) -
The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
por: Stein, R. C., et al.
Publicado: (1990) -
Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer.
por: Davies, J. H., et al.
Publicado: (1992) -
Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)